←
Zara Baloch631 posts
Zara Baloch avatar

Zara Baloch

@zarabaloc

Physician | Match 2027 IM Residency Applicant | Oncology, wellness & longevity | Medical Correspondent & Leadership @mednewsweek

◷ Joined March 2019▧ 61 Photos and videos
Al-Ola A Abdallah MD (USMIRC) avatar
⟳ Zara Baloch retweeted
Al-Ola A Abdallah MD (USMIRC)@Abdallah81MD·17h

📣 It’s official! Meet the 28 speakers, moderators, and panelists for the National ICE-T Congress in Oklahoma City on January 30, 2027. Join us for live debates in myeloma, lymphoma, and myeloid disease. Swipe to meet the faculty. See you in OKC! 👇 #ICETCongress #CellularTherapy @kczmj @Taha_CancerDoc @msalmanfaisal @Larvol @OpenMedKate @YLeyfman @zarabaloc @CancerNetwrk @oncodaily @US_HMC @USMIRCNEWS @Maho_VuMedi_Hem @VuMediHemOnc @CurrentOncology

Post attachmentPost attachment
Zara Baloch avatar
Zara Baloch@zarabaloc·Nov 14

An excellent start to the @MedNewsWeek Clinical Exchange series! From chemotherapy-free approaches to the evolving role of CAR-T and bispecific antibodies, Dr. Kami Maddocks and Dr. Peter Martin explore some of the most pressing questions in mantle cell lymphoma care. A fascinating discussion on where treatment is today and where it could be heading next. 🎥 A must-watch for anyone interested in the future of lymphoma care! Watch the full episode: lnkd.in/dkyM4A-y

Honored to share the inaugural @MedNewsWeek x @oncodaily Clinical Exchange on Mantle Cell Lymphoma: Where Practice Is Heading, featuring Dr @kmaddmd and Dr Peter Martin. A conversation built around the clinical decisions shaping MCL care today. 1/4

Post attachmentPost attachment
Al-Ola A Abdallah MD (USMIRC) avatar
⟳ Zara Baloch retweeted
Al-Ola A Abdallah MD (USMIRC)@Abdallah81MD·Nov 12

Here are the top 11 abstracts and (all were scored fairly) at #ASH2026 that I believe will show main impact : 1. AQUILA · Abstract #112 · 9.8/10 1/3 Does treating high-risk smoldering myeloma help patients live longer? My #1 #ASH26 abstract is AQUILA (#112), daratumumab vs active monitoring in high-risk SMM. My score: 9.8/10. 2/3 Among 390 randomized patients, 7-year overall survival was 87.8% with daratumumab vs 78.7% with monitoring. That’s a 9.1-point absolute difference. Median PFS was 82.5 vs 34.9 months. 3/3 This changes my conversation with an asymptomatic patient. Once we confirm high-risk SMM and exclude active myeloma, we can weigh up to 3 years of treatment against a measurable survival benefit. #mmsm #myeloma #USMIRC #MedEd #medtwitter @USMIRCNEWS @US_HMC @Larvol @OpenMedKate @oncodaily

Post attachmentPost attachment
Adeena Musheer, MBBS avatar
⟳ Zara Baloch retweeted
Adeena Musheer, MBBS@MusheerAdeena·Nov 11

Mantle Cell Lymphoma: Where Practice Is Heading explores the clinical questions increasingly shaping MCL care: from frontline treatment and high-risk disease to MRD, BTK inhibitors, CAR-T, bispecific antibodies, and therapeutic sequencing.

Post attachment
Adeena Musheer, MBBS avatar
⟳ Zara Baloch retweeted
Adeena Musheer, MBBS@MusheerAdeena·Nov 11

Honored to welcome Dr. @kmaddmd and Dr. Peter Martin to @MedNewsWeek x @oncodaily for our Clinical Exchange on Mantle Cell Lymphoma. We are deeply grateful to both for their time, expertise, and generosity in joining this educational conversation.

0:30
USMIRC News avatar
⟳ Zara Baloch retweeted
USMIRC News@USMIRCNEWS·Oct 15

Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies #USMIRC @USMIRCNEWS #myeloma @Cancers_MDPI @AtrashShebli @Abdallah81MD @mumairmushtaq #mmsm

Post attachment

Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies #USMIRC @USMIRCNEWS #myeloma url.us.m.mimecastprotect.com…

Yan Leyfman, MD avatar
⟳ Zara Baloch retweeted
Yan Leyfman, MD@YLeyfman·Nov 10

Excited to be joining CancerNetwork as a medical correspondent at the 44th Annual Chemotherapy Foundation Symposium (#CFS2026) in New York City! Looking forward to engaging with leading experts in oncology, discussing emerging clinical evidence, and highlighting the scientific advances shaping the future of cancer care. It's a privilege to help bring these conversations and expert perspectives to the broader oncology community. Grateful to the CancerNetwork, OncLive, and PER teams for the opportunity to contribute to meaningful scientific dialogue and education. Looking forward to an exciting few days of learning, collaboration, and conversations at the forefront of oncology! #CFS2026 #CancerNetwork #Oncology #CancerResearch #CancerCare #MedicalEducation @CancerNetwrk @gotoPER @OncLive

MedNews Week will be on the ground in New York City starting tomorrow for the 44th Annual Chemotherapy Foundation Symposium (#CFS2026)! 🗽 Led by Dr. Yan Leyfman, our team will be bringing you the latest insights, expert perspectives, and engaging conversations on emerging advances in cancer research and treatment. Looking forward to seeing our team connect with leaders in oncology and share meaningful discussions with the global medical community. Stay tuned for exclusive coverage from NYC! @MedNewsWeek @YLeyfman @shahzeenkadir1 @The_Noam_Levi @OncLive #MedNewsWeek #Oncology #CFS2026

Post attachment
Zara Baloch avatar
Zara Baloch@zarabaloc·Nov 10

MedNews Week will be on the ground in New York City starting tomorrow for the 44th Annual Chemotherapy Foundation Symposium (#CFS2026)! 🗽 Led by Dr. Yan Leyfman, our team will be bringing you the latest insights, expert perspectives, and engaging conversations on emerging advances in cancer research and treatment. Looking forward to seeing our team connect with leaders in oncology and share meaningful discussions with the global medical community. Stay tuned for exclusive coverage from NYC! @MedNewsWeek @YLeyfman @shahzeenkadir1 @The_Noam_Levi @OncLive #MedNewsWeek #Oncology #CFS2026

Post attachment
Yan Leyfman, MD avatar
⟳ Zara Baloch retweeted
Yan Leyfman, MD@YLeyfman·Nov 10

Excited to be attending the 44th Annual Chemotherapy Foundation Symposium (CFS 2026) in New York City! Looking forward to connecting with leading voices in oncology, exploring the latest advances in cancer therapeutics, and bringing you insights directly from the meeting. From emerging treatment strategies to innovations reshaping cancer care, I'll be sharing conversations with experts at the forefront of the field. Grateful to the CancerNetwork, Onclive & PER team for the opportunity to help bring these important discussions to the broader oncology community. Stay tuned for interviews, expert perspectives, and highlights from #CFS2026! #Oncology #CancerResearch #CancerNetwork #CancerCare #MedicalInnovation #CFS2026 @CancerNetwrk @gotoPER @OncLive

🚨 The 44th Annual Chemotherapy Foundation Symposium is approaching! Yan Leyfman, MD (@YLeyfman), will be live on the scene. Stay tuned tomorrow! #Oncology #Cancer #CFS | @gotoPER

0:59
Al-Ola A Abdallah MD (USMIRC) avatar
⟳ Zara Baloch retweeted
Al-Ola A Abdallah MD (USMIRC)@Abdallah81MD·Nov 10

I am not, and I will never be, just a writer. I aspire to be a builder! I have never measured academic success by the number of papers published, guidelines written, or five-minute presentations delivered at conferences. For me, these are tools, not the ultimate goal. If they do not contribute to a larger vision, they become nothing more than additional lines on a CV. Throughout my career, I have had the privilege of working alongside giants who taught me that physicians should not only advance science but also build institutions, establish programs, and create systems that transform patient care for generations. Two remarkable leaders have profoundly shaped this belief. Dr. Roy Jensen, Director of The University of Kansas Cancer Center, helped transform our institution into an NCI-designated Comprehensive Cancer Center, established an exceptional research enterprise, and created a lasting legacy for Kansas. With the new cancer center building on the horizon, we are approaching another major transformation in cancer care across the Midwest. Dr. Joseph McGuirk built an extraordinary transplant and cellular therapy program @KUcancercenter , helping position our cancer center among the nation’s leading institutions in the treatment of myeloma, lymphoma, and leukemia. What inspires me most about these leaders is not simply their individual accomplishments, but what they have built for others and for future generations. My dream is to build a truly unique, comprehensive, multidisciplinary Plasma Cell Disorders Program within The University of Kansas Cancer Center. A program that integrates clinical excellence, research, innovation, education, and collaboration across specialties to advance the care of patients with multiple myeloma, amyloidosis, and other plasma cell disorders. A program that brings specialists together around a shared mission: delivering the best possible care to our plasma cell disorder patients. A program that becomes bigger than any one individual and continues to grow long after its founders have moved on. Is it ambitious? Absolutely. Is it difficult? Without question. Is it possible? I believe it is. I have tremendous respect for academic research and those who dedicate their careers to advancing knowledge. However, I have always believed that the greatest legacy of a physician is defined not only by what they publish, but also by what they build and leave behind. And I constantly remind myself of one thing: I am not, and I will never be, just a writer. I aspire to be a builder. Because one day, when I look back on my career, I hope to see more than a long list of publications. I hope to see a program, a team, and a system that continue to transform patients’ lives long after I am gone. That, to me, is the true meaning of academic leadership. #AcademicMedicine #Leadership #PlasmaCellDisorders #MultipleMyeloma #Amyloidosis #CancerCare #HealthcareInnovation

Post attachmentPost attachment
Yan Leyfman, MD avatar
⟳ Zara Baloch retweeted
Yan Leyfman, MD@YLeyfman·Nov 8

From Cancer Data to Discovery: Advancing the Future of AI in Oncology The future of cancer care will be shaped not only by the therapies we develop, but by how effectively we harness data, leverage artificial intelligence, and translate innovation into meaningful opportunities for patients worldwide. It was a tremendous honor to be invited as a Featured Speaker at the National Cancer Institute's 4th Annual Office of Data Sharing Symposium, where I had the opportunity to present our work exploring the utility of AI-driven, mCODE-aligned frameworks to facilitate clinical trial matching and advance oncology data sharing. My sincere gratitude to Dr. Ying Huang for the gracious invitation, and to Drs. Huang and Mousumi Ghosh for their exceptional leadership in organizing such an outstanding forum and bringing together a remarkable group of speakers at the forefront of cancer research, AI, and data science. I am especially grateful to Dr. Bonilla for his continued mentorship, guidance, and belief in the potential of our work, and to the incredible MassiveBio team for their tireless efforts to bridge the gap between scientific innovation and patient access to clinical trials. One of the most rewarding aspects of the symposium was the opportunity to connect with pioneering leaders in AI, including Dr. Caroline Chung, as well as Drs. Kelli Rasmussen, Satish Viswanath, Xueli Liu, and Jaime Guidry Auvil as we exchanged perspectives on where the intersection of AI, oncology, and data science is heading. These conversations reinforced an important conviction: the true measure of innovation is not simply what technology can accomplish, but how many lives it can meaningfully impact. As we look toward the next generation of cancer care, I believe our greatest opportunity lies in building a future where AI-driven discoveries transcend institutional, geographic, and socioeconomic boundaries, bringing precision oncology and clinical trials within reach of patients everywhere. I leave this symposium inspired by the extraordinary work being done across the field, grateful for the opportunity to contribute to these conversations, and even more committed to helping translate these advances into equitable, real-world impact. The future of oncology will not be built in isolation. It will be built through collaboration, shared knowledge, and a collective commitment to ensuring that innovation reaches every patient who needs it. #NCI #ArtificialIntelligence #Oncology #ClinicalTrials #PrecisionMedicine #CancerResearch #HealthEquity #DataScience #CancerInnovation

Post attachment
Current Oncology avatar
⟳ Zara Baloch retweeted
Current Oncology@CurrentOncology·Nov 5

📣3 days to ICE-T Conference! Attending? Turn your presentation into a paper for our @CurrentOncology Special Issue on Cellular Therapy, guest-edited by Dr. Abdallah.🔬 👉Register for the meeting: bit.ly/4AyTDIT 🔗Submit to the Special Issue: bit.ly/4f7p04D

📣 43 speakers, panelists, and moderators. Multiple specialties. One shared mission: advancing cellular therapy. Join us at the ICE-T Conference on November 7, 2027, in Kansas City, bringing together experts from across the United States—including oncologists, hematologists, neurologists, rheumatologists, stem cell transplant specialists, pharmacists, nurses, and nurse practitioners. Through expert presentations, hands-on workshops, and interactive panel discussions, we will explore advances in cellular therapy, share practical insights, and strengthen collaboration across specialties and care settings. From research to practice, and from referral to survivorship—every perspective matters. 📍 Kansas City | 🗓️ November 7, 2027 lnkd.in/g9kbqa2R #ICETCongress #CellularTherapy #CART #BispecificAntibodies #Hematology #Oncology #MultidisciplinaryCare

Post attachment